-
Je něco špatně v tomto záznamu ?
Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing
N. Jankovska, R. Matej
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
00064165
MH CZ - DRO: Conceptual Development of Research Organization, the General University Hospital, Prague
00064190
MH CZ - DRO: Conceptual Development of Research Organization, the Thomayer University Hospital, Prague
NV19-04-00090
the Grants Agency of the Ministry of Health
NV18-04-00179
the Grants Agency of the Ministry of Health
GAUK 142120
Univerzita Karlova v Praze
Project Progress Q27/LF1
Univerzita Karlova v Praze
NLK
Directory of Open Access Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Despite an early understanding of amyotrophic lateral sclerosis (ALS) as a disease affecting the motor system, including motoneurons in the motor cortex, brainstem, and spinal cord, today, many cases involving dementia and behavioral disorders are reported. Therefore, we currently divide ALS not only based on genetic predisposition into the most common sporadic variant (90% of cases) and the familial variant (10%), but also based on cognitive and/or behavioral symptoms, with five specific subgroups of clinical manifestation-ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, the fully developed behavioral variant of frontotemporal dementia in combination with ALS, and comorbid ALS and Alzheimer's disease (AD). Generally, these cases are referred to as amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD). Clinical behaviors and the presence of the same pathognomonic deposits suggest that FTLD and ALS could be a continuum of one entity. This review was designed primarily to compare neuropathological findings in different types of ALS relative to their characteristic locations as well as the immunoreactivity of the inclusions, and thus, foster a better understanding of the immunoreactivity, distribution, and morphology of the pathological deposits in relation to genetic mutations, which can be useful in specifying the final diagnosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024274
- 003
- CZ-PrNML
- 005
- 20211013134007.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/diagnostics11081365 $2 doi
- 035 __
- $a (PubMed)34441299
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jankovska, Nikol $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, 140 00 Prague, Czech Republic
- 245 10
- $a Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing / $c N. Jankovska, R. Matej
- 520 9_
- $a Despite an early understanding of amyotrophic lateral sclerosis (ALS) as a disease affecting the motor system, including motoneurons in the motor cortex, brainstem, and spinal cord, today, many cases involving dementia and behavioral disorders are reported. Therefore, we currently divide ALS not only based on genetic predisposition into the most common sporadic variant (90% of cases) and the familial variant (10%), but also based on cognitive and/or behavioral symptoms, with five specific subgroups of clinical manifestation-ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, the fully developed behavioral variant of frontotemporal dementia in combination with ALS, and comorbid ALS and Alzheimer's disease (AD). Generally, these cases are referred to as amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD). Clinical behaviors and the presence of the same pathognomonic deposits suggest that FTLD and ALS could be a continuum of one entity. This review was designed primarily to compare neuropathological findings in different types of ALS relative to their characteristic locations as well as the immunoreactivity of the inclusions, and thus, foster a better understanding of the immunoreactivity, distribution, and morphology of the pathological deposits in relation to genetic mutations, which can be useful in specifying the final diagnosis.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Matej, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, 140 00 Prague, Czech Republic $u Department of Pathology, First Faculty of Medicine, Charles University, General University Hospital, 128 00 Prague, Czech Republic $u Department of Pathology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
- 773 0_
- $w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 11, č. 8 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34441299 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013134004 $b ABA008
- 999 __
- $a ind $b bmc $g 1708257 $s 1144771
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 11 $c 8 $e 20210729 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
- GRA __
- $a 00064165 $p MH CZ - DRO: Conceptual Development of Research Organization, the General University Hospital, Prague
- GRA __
- $a 00064190 $p MH CZ - DRO: Conceptual Development of Research Organization, the Thomayer University Hospital, Prague
- GRA __
- $a NV19-04-00090 $p the Grants Agency of the Ministry of Health
- GRA __
- $a NV18-04-00179 $p the Grants Agency of the Ministry of Health
- GRA __
- $a GAUK 142120 $p Univerzita Karlova v Praze
- GRA __
- $a Project Progress Q27/LF1 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20211006